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RÉSUMÉ 
 
Pendant les trente dernières années, le taux d'incidence du cancer de la thyroïde chez l'homme 
et la femme a considérablement augmenté partout dans le monde. Cependant, on estime que 
d'ici à 2019 le cancer de la thyroïde deviendra le troisième cancer le plus répandu chez les 
femmes dans tous les groupes d'âge en raison de la tendance d’augmentation plus dramatique 
chez elles. En général, il n'y a aucune raison claire qui explique l'augmentation mondiale de 
l'incidence du cancer de la thyroïde et il est émis l'hypothèse que cette recrudescence de 
l'incidence a une étiologie multifactorielle. Bien qu'il soit clair que le progrès technique des 
modalités de l’imagerie diagnostique telle que l'échographie peut amener à une augmentation 
du taux de détection du cancer de la thyroïde secondaire au sur-diagnostic des maladies sous-
cliniques, il existe des preuves fortes indiquant une vraie augmentation du cancer de la thyroïde. 
La cartographie cervicale échographique préopératoire est un outil important dans l'algorithme 
diagnostic du cancer de la thyroïde. Elle aide à identifier l’étendue des métastases ganglionnaires 
cervicales afin de guider la dissection chirurgicale anticipée. La dissection chirurgicale du cou 
orientée selon les compartiments anatomiques et guidée par la cartographie cervicale 
échographique peut amener à une réduction des risques des complications postopératoires et des 
récidives tumorales locorégionales. 
Nous avons effectué une analyse qualitative et quantitative de la cartographie cervicale 
échographique afin d'évaluer la fiabilité diagnostique de ce test. Nos résultats ont démontré une 
valeur prédictive positive assez élevée de cette modalité diagnostique ainsi q’une association 
quantitative forte entre les données de la cartographie échographique et les résultats de 
l’histopathologie. Nous suggérons que l’utilisation de la cartographie cervicale échographique 
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cible les patients présentant un risque plus important d’une maladie persistante / récidivante. 
 
Mots-clés : cancer de la thyroïde, cartographie cervicale échographique, valeur prédictive 
positive, analyse qualitative et quantitative. 
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ABSTRACT 
 
Over the last 30 years, the incidence rate of thyroid cancer has drastically increased in both 
genders all over the world. However, due to a more dramatic pattern in females, it is estimated 
that by 2019 it will become the third most prevalent cancer in women of all ages. 
Overall, there are no clear reasons behind the worldwide increase in thyroid cancer incidence 
and it is hypothesized that this upsurge has a multifactorial etiology. Despite the fact that recent 
advances in imaging modalities such as ultrasound can lead to thyroid cancer overdiagnosis by 
improving the detection rate for subclinical disease, there is strong evidence indicating a true 
increase in the occurrence of thyroid cancer as well.   
Preoperative ultrasound cervical mapping, an important tool in the diagnostic algorithm of 
thyroid cancer, helps to identify metastatic spread in cervical lymph nodes and guides the 
surgeon for subsequent surgical dissection. Compartment oriented neck dissection directed by 
ultrasound mapping decreases locoregional tumor recurrence and lowers the risk of postsurgical 
complications. 
We conducted a qualitative and quantitative analysis of ultrasound mapping to evaluate this 
test’s diagnostic reliability. Our results demonstrated that the positive predictive value of this 
diagnostic modality was sufficiently high and that there was a strong quantitative association 
between ultrasound mapping and histopathology results. We therefore recommend that 
ultrasound mapping be used to target patients with a higher risk of persistent or recurrent thyroid 
cancer. 
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Historical background (1)  
 
The thyroid gland was first described by anatomist Andrea Vesalius in 1543 in his inauguration 
of modern anatomy “De Humani Corporis Fabrica” published in Switzerland. 
Later, Julius Casserius (1545–1616) drew the first distinct image of the thyroid gland in a 
classical horseshoe shape. In 1656, Thomas Wharton named it “glandula thyreoidea” not 
because of its shape (thyreos in Greek means “shield”) but because it resembles nearby 
anatomical structures such as the thyroid cartilage of the larynx [1, 2]. The first surgical removal 
of the thyroid gland was described by German surgeon Lorenz Heister in 1742 [2]. 
 
Embryology (2) 
 
The thyroid gland is the first endocrine structure to appear during the embryological 
development of the human body starting around the 4th week of gestation [1, 3]. It is a composite 
of two different cell types which have two distinct embryological origins. The major part of the 
thyroid is composed of epithelial cells which have an endodermal origin and arise from the 
primitive pharynx. Later in development, these cells become thyroid follicular cells (TFCs) 
which are responsible for producing thyroid hormones such as triiodothyronine (T3) and 
thyroxine (T4). The thyroid gland’s second embryological component is the neural ectoderm 
from the ultimobranchial body (fifth pharyngeal pouch) which gives rise to parafollicular cells 
or calcitonin-producing C cells [4-6]. Precursors of the C cells migrate from the neural crest to 
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the fourth pharyngeal pouch which is symmetrically located on both sides of the neck [5]. C 
cells subsequently reach their final position within the upper third of the thyroid lobes where 
they comprise only 1-2% of the thyroid cell mass [4].  
Several developmental steps take place before mature thyroid gland formation [5].  Around the 
20th embryonic day, the thyroid anlage develops as part of the endodermal epithelium in the 
midline of the primitive pharynx [5]. 
The foramen caecum, which is the endodermal bud between the first and second branchial 
arches, gives rise to the principle cells responsible for the thyroid gland’s structural and 
functional integrity [3].  The foramen caecum lies at the intersection of the tongue’s midline and 
the sulcus terminalis which defines the border between the oral (anterior two-thirds) and 
pharyngeal (posterior third) parts of the tongue [2, 3]. In adults, the circumvallate papillae 
delineate this border which also corresponds to the tongue’s ectodermal-endodermal boundary 
[3]. The TFC proliferation results in the formation of the initial thyroid primordium. The 
formation then starts to thicken and invaginates inferiorly, and this transformation forms a 
tubular structure called the thyroid diverticulum [3, 7]. As it continues to migrate caudally, it 
transforms into a bilobed and solid structure which eventually reaches its final position on the 
inferior aspect of the anterior neck. The migration process is completed by the 45th day and the 
thyroid gland lies inferiorly to the larynx, around the anterior and lateral sides of the trachea [3]. 
The migratory route from the foramen caecum to the final cervical position is called the 
thyroglossal tract [8]. During late embryological development, the thyroglossal duct regresses 
and becomes fibrotic. The foramen caecum then involutes into a vestigial pit that can be 
visualized in 60% of adults at the base of the tongue [3]. During the process of migration, 
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different deviations from the normal development route may occur. Occasionally, the 
thyroglossal duct fails to atrophy, leaving accessory or ectopic thyroid tissue along the migratory 
path. These islands of ectopic tissue transform into neoplasia in rare cases. More commonly, 
they may become metabolically active but the amounts of produced hormones are minimal 
without the main gland [3].  Rarely, the thyroid gland fails to descend into the neck, resulting in 
a lingual thyroid [7]. In this condition, a mass is noted in the posterior oral tongue, and the 
patient may complain of dysphagia, dysphonia, and dyspnea [3, 8]. Although a maldescended 
thyroid may not function appropriately, it is essential to keep in mind that a lingual thyroid may 
be the only functional thyroid tissue present [3, 8]. If it is removed due to its mass effect, 
subsequent replacement therapy should be administered to prevent further aggravation of the 
patient’s hypothyroid state. Cysts and sinuses are other morphological patterns of failed 
involution of the thyroglossal duct. These lesions are typically located in the midline, around 
the level of the hyoid bone. Infections and inflammatory processes are common pathologic 
manifestations of those congenital malformations, and antibiotics along with planned surgical 
intervention are the standard of care in advanced cases. 
Simultaneously to the thyroid’s migration process, the C cells in the 4th pharyngeal pouch are 
positioned in the ultimobranchial body. First, the ultimobranchial bodies migrate from their 
lateral origin to a medial position on either side of the neck. By week 10, the main 
histophysiologic units of the mature and differentiated thyroid gland such as TFCs and C cells 
have merged at the front of the cricoid cartilage on the trachea. The thyroid gland then starts to 
enlarge and the TFCs, which notably outnumber the interspersed C cells, begin to organize into 
follicles. The final dispersion of C cells within the thyroid is not uniform, as they are mostly 
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localized in the middle and upper thirds of the gland’s lateral lobes [5]. The C cells comprise 
only 1-2% of the thyroid cell mass [4]. The final stage in normal organogenesis of the gland is 
a functional differentiation of the TFCs, which later lead to hormone production [5].  
Functional differentiation of TFCs and C cells occurs along with the thyroid migration process 
and is regulated by relevant controller genes. The natural drive of thyroid morphogenesis is 
closely related to transcription factors such as TTF-1, TTF-2, Foxe1, Hhex, and PAX-8, which 
are essential for the thyroid’s normal development and migration [5, 8].  The simultaneous 
presence of these genes is essential for recruiting TFCs and organizing the thyroid bud. They 
continue to promote further development of the thyroid until it has completed migration and 
starts to enlarge [5]. At this point, other genes take over the functional development, and 
pathways for hormone synthesis start to activate. There are three functional stages in thyroid 
development: precolloid, colloid, and follicular. They occur approximately at 7 weeks to 12 
weeks, 13 weeks to 14 weeks, and after 14 weeks. Hormone production in the thyroid starts at 
around 12 weeks [8].  
 
Histology (3) 
 
Histologically, the main architectural units of the thyroid gland are numerous hollow sacs called 
thyroid follicles. The  connective tissue septa separates the thyroid gland into groups of 20-40 
follicles [9]. The follicles contain colloid at their center and a simple cuboidal epithelium 
composes their main lining. Staining with hematoxylin and eosin produces a uniformly pink 
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color in the colloid lumen. The follicular cells’ principal role is to produce thyroid colloid, which 
contains high quantities of thyroglobulin and iodide. 
The colloid is then extruded into the follicular lumen for future use. Subsequently, thyroid-
stimulating hormone (TSH), which is the main regulator of the gland’s functional activity, 
stimulates the conversion of the colloid precursor into mature thyroid hormone. Although 
follicular cells are single layered and usually cuboidal in shape, their architecture may be 
significantly affected by the general metabolic state of the gland. In the event of high metabolic 
demand for thyroid hormones, the amount of colloid goes down as a consequence of its 
increased conversion into mature thyroid hormones. The follicular cells may also change their 
shape and become columnar. In cases of relative hypoactivity of the gland, the follicular lumen 
becomes larger as more colloid is stored in preparation for future use. Decreased metabolic 
activity causes the follicular cells to flatten and become smaller in size. Although most authors 
believe the monoclonal origin of thyroid cells, there is some evidence showing the polyclonal 
origin of thyroid cells with different malignant potential for each group of cells [10]. The next 
level of the thyroid’s functional and structural organization is the parafollicular cells (C cells) 
which produce calcitonin. They are situated in the stroma, between thyroid follicles.  To better 
view these cells, immunostains such as immunoperoxidase are the preferred method [3].   
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Anatomy (4) 
 
The mature thyroid gland is an H- or U-shaped bilobed, butterfly-shaped endocrine organ which 
is located on the anterolateral aspect of the cricothyroid membrane, cricoid and trachea [3, 5, 9]. 
Depending on gender and age, the normal thyroid in an adult weighs around 12-25 g, which 
corresponds to a volume of 12-20 ml [4, 5]. Usually, it is slightly larger in men. The isthmus of 
the gland connects the right and left lobes of the thyroid. On ultrasonography the average size 
of each lobe is 4 cm long vertically and 1-1.5 cm wide with a thickness of 1 cm. [3]. In some 
cases there is an extension of thyroid tissue which arises from the isthmus. This tissue, known 
as the pyramidal lobe, goes superiorly along the midline and is a remnant of the embryologic 
thyroglossal duct [3]. 
 There are three main anatomical borders separating the thyroid from neighboring structures. 
The trachea and esophagus are the demarking posteromedial boundaries; the carotid sheath and  
sternocleidomastoid muscles are the limiting lateral and anterolateral boundaries respectively 
[5]. The thyroid extends from the level of the fifth cervical vertebra to the first thoracic vertebra. 
An extension of the pretracheal fascia (Berry’s ligament) composes the fibrous capsule of the 
thyroid which serves as a supporting structure. The septae of the capsule divide the gland into 
macroscopic lobules. Arterial and venous branches run along the septae within the connective 
tissue. The visceral part of pretracheal fascia is attached anteriorly to the crycoid and thyroid 
cartilage [5, 8]. The muscular part of the pretracheal fascia encloses three pairs of infrahyoid 
muscles, namely the sternohyoid, sternothyroid, and thyrohyoid [8]. Because of its firm 
attachments, the thyroid may move superiorly as a consequence of tracheal elevation during 
7 
 
swallowing [3].  This has some diagnostic value as it helps to differentiate thyroid masses (such 
as thyroid nodules) and congenital malformations (such as thyroglossal duct cysts). In contrast 
to lymphadenopathy or branchial cleft cysts which remain stationary during swallowing, thyroid 
nodules and thyroglossal duct cysts are freely movable [3].  
 
Blood Supply (4.1) 
 
The arterial blood supply to the thyroid is the richest per gram of tissue [3, 4]. The external 
carotid artery and the thyrocervical trunk give rise to the superior and inferior thyroid arteries 
respectively. The superior thyroid artery supplies the upper pole and passes in a caudal direction 
from the external carotid artery [4, 8].  The inferior thyroid artery supplies the posterior part of 
the gland and runs in a cranial direction [4].  There may be a third, relatively uncommon, arterial 
supply from the brachiocephalic trunk called the arteria thyroidea ima (3%-10%) [2, 5, 8]. While 
arterial blood is circulated by two pairs of arteries, venous outflow is through three main venous 
pathways named the superior, middle, and inferior thyroid veins. The superior thyroid vein 
accompanies the superior thyroid artery and, along with the middle thyroid vein, drains into the 
internal jugular vein [2, 3]. There is some risk of rupture of the middle thyroid vein during 
thyroidectomy as it has a posterior course and can be damaged in forward traction of the gland 
[2].  Usually, there are several inferior thyroid veins that drain either into the internal jugular or 
the brachiocephalic veins.  
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Lymph Drainage (4.2) 
 
The thyroid has a very rich lymphatic system. It consists of an intra and extraglandular network 
with developed lymph vessel anastamoses that drain each part of the gland in multiple different 
directions [4, 8, 11]. This can explain the frequent intraglandular spreading and multifocal 
distribution of thyroid neoplasias. 
The lateral and medial aspects of the gland have some topographic differences in their lymphatic 
drainage. The lymphatic vessels of the gland’s lateral part pass along the arteries. They may 
ascend across the superior thyroid artery or descend across the inferior thyroid artery before 
reaching their final pool in the jugular chain of cervical nodes. Between the superior and inferior 
thyroid arteries, lymphatic vessels may drain directly into the jugular nodes. The lymphatic 
vessels of the gland’s medial part also drain in two directions: superiorly to the digastric nodes 
and inferiorly to the paratracheal and brachiocephalic nodes [2, 6]. In the midline, just above the 
isthmus of the thyroid, lies the Delphian node (named after the Oracle of Delphi). An abnormal 
looking Delphian node may have some diagnostic value as nodal metastases are common in 
thyroid cancer [8]. 
There are two main drainage pathways for the periglandular lymph network. The first pathway 
originates from lymph nodes and lymph vessels in the central zone of the neck. It is positioned 
between the carotid sheaths and extends in a downwards direction including pre and paratracheal 
regions. From this point, the lymph drainage may branch with the mediastinal lymphatic system. 
The second lymph drainage pathway (secondary drainage) arises from the lateral region of the 
neck. It involves the lymph vessels and lymph nodes along the jugular vein as well as lymphatic 
9 
 
structures extending up towards the submandibular region. Lymph nodes in the supraclavicular 
triangle are also part of the secondary drainage network [4].  
The thyroid’s dense lymphatic network is closely linked to the concept of a stepwise progression 
of nodal metastasis. This has enormous clinical relevance, as a nodal metastasis from one nodal 
station to another is directly correlated with the extent of the neck dissection and  radiation 
therapy in patients with thyroid cancer [11]. Sentinel lymph node studies about the pattern of 
thyroid lymphatic drainage revealed some consistency in the dispersion of metastasis in different 
malignancies. The first metastases extend into the nodes of the central compartment of the neck 
(pre and paratracheal stations) followed by the nodes of the superior mediastinum and the lateral 
cervical nodes. The neck’s lymphatic mapping is often described in terms of “levels” ranging 
from level I to level VI. Level VI nodes are located in the central compartment which is bounded 
by the hyoid bone superiorly, the suprasternal notch inferiorly, and the carotid arteries laterally. 
There are three nodal groups in the level VI compartment that are responsible for thyroid 
drainage: paralaryngeal, paratracheal, and prelaryngeal (Delphian). Levels III, IV, and V are 
part of the lateral cervical compartments which are commonly affected by bilateral metastasis. 
Level III consists of lymph nodes located around the middle third of the internal jugular vein. It 
extends from the lower side of the body of the hyoid bone (superiorly) to the lower side of the 
cricoid cartilage arch (inferiorly). From anterior to posterior this zone is limited by the lateral 
border of the sternohyoid muscle and the posterior border of the sternocleidomastoid muscle[12, 
13]. Level IV consists of LNs located around the lower third of the internal jugular vein. It 
extends from the lower side of the cricoid cartilage arch (superiorly) to the level of clavicle 
(inferiorly). The anterior boundary is the lateral border of the sternohyoid muscle, and the 
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posterior boundary is the posterior border of the sternocleidomastoid muscle[12-14]. Level V is 
comprised of the LNs in the posterior triangle. The boundaries of the triangle are the anterior 
border of the trapezius muscle posteriorly, the posterior border of the sternocleidomastoid 
muscle anteriorly, and the clavicle inferiorly[12-14]. Lymph nodes lying superiorly to the 
innominate vein in the superior mediastinum compose level VII  [11]. 
  
 
Nerves (4.3) 
 
The recurrent laryngeal nerve (RLN) provides motor and sensory innervations of the larynx. 
The RLN is responsible for phonation as well as swallowing, and any significant damage to this 
nerve can cause dysphonia and varying degrees of dysphagia [4, 5]. Considering the close 
location of the thyroid gland to the RLN path, there is a risk of RLN infiltration or compression 
by thyroid cancers, followed by impairment of function [4]. The RLN is a branch of the vagus 
which has different courses on both sides of the neck. On the right, the nerve loops posteriorly 
to the subclavian artery, then extends up until it reaches the tracheoesophageal groove. In 
contrast, the nerve on the left side loops posteriorly to the arch of the aorta, followed by an 
ascending course in the tracheoesophageal groove [2, 7]. Along its path the RLN also innervates 
the trachea and esophagus by multiple small branches [2]. The RLN carries motor, sensory, and 
parasympathetic fibers. The external branch of the nerve is responsible for the motor function 
of 4 intrinsic muscles (lateral cricoarytenoid, posterior cricorytenoid, transverse and oblique 
interarytenoid and thyroarytenoid) of the larynx. The internal branch of the RLN supplies 
sensation to the vocal cords and subglottic region. The RLN also sends branches to the inferior 
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constrictor and cricopharyngeus muscles before entering the larynx [15]Another important 
branch of the vagus is the superior laryngeal nerve which runs in a caudal direction along the 
superior thyroid artery. After passing behind the internal carotid artery, it divides into external 
and internal branches. The motor/external branch supplies the cricothyroid muscle, and damage 
to this nerve also results in voice changes [4].  
 
Physiology (5) 
 
The principal purpose of the thyroid gland is to provide adequate amounts of L-thyroxine (T4) 
and, to a much lesser extent, L-triiodthyronine (T3) which are essential for normal body 
metabolism, growth, and development. Both T4 and T3 are iodinated hormones which require 
the thyroid to be able to extract circulating iodide from the bloodstream for further organification 
and incorporation into the thyroid hormone molecules [9]. The thyroid’s level of activity and 
the amount of produced hormones are tightly regulated on several levels, both within and outside 
the gland. Those regulating mechanisms may have first line clinical relevance in thyroid cancer 
as the cancerous cells originate from normal thyroid cells. Depending on the level of 
dedifferentiation, the cancerous cells may use cellular mechanisms that are identical to those of 
normal cells in order to remain viable. In clinical settings these similarities help to identify, 
characterize, and finally treat different malignancies of the thyroid [9].  
In order for the thyroid gland to provide the necessary amount of physiological hormones, an 
adequate supply of dietary iodine is essential. Both high and low iodine-containing diets may 
cause a vast range of serious problems. One of the most detrimental complications of over or 
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undersupply of dietary iodine is thyroid cancer. There is some evidence showing a higher 
incidence rate of papillary thyroid cancer in areas where there is an abundance of dietary iodine 
[16].  Meanwhile, low iodine intake may increase the proportional incidence of follicular thyroid 
cancer [8]. Administration of excess pharmacologic doses of iodine may inhibit iodide 
organification and thyroglobulin (Tg) proteolysis followed by an acute decrease in thyroid 
hormone production and release. This phenomenon, known as Wolff–Chaikoff effect, is 
explained by oversaturation of the sodium-iodine symporter (NIS). However, this effect does 
not last long as the gland adapts quickly to the new conditions and downregulates the uptake of  
iodine despite its continuously high plasma levels [9, 11]. 
One of the most critical steps in thyroid hormone formation is the transportation of the iodine 
into TFCs against an electrochemical gradient [11]. This is a saturable, energy dependent 
process which requires oxidative phosphorilation [11]. The main system that provides the 
necessary influx of iodine into the TFCs is NIS, which is a transmembrane protein located in 
the basolateral membrane of the thyrocyte [9, 11]. NIS cotransports sodium and iodide in a 2:1 
ratio using the transmembrane sodium gradient as a driving force in order to stimulate iodide 
uptake into follicles [3]. The expression level of NIS on TFCs is responsive to different 
regulatory factors including TSH, and this mechanism is widely used in clinical settings. After 
intense TSH stimulation, malignant thyrocytes of papillary, follicular, and Hurthle cell cancers 
increase the uptake of I-131 as NIS is also present in their membrane [11]. However, in some 
types of thyroid cancer, NIS either does not have enough sensitivity or is completely absent 
which makes treatment with radioactive iodine practically useless [11]. Apart from therapeutic 
purposes, the NIS transporter concept can serve as a valuable diagnostic tool in patients with 
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differentiated thyroid cancers (papillary and follicular cancers) who underwent a thyroidectomy. 
In this case, the whole body scan with radiotracer can discover residual functioning thyroid 
tissue or actively functioning metastasis which can be retreated with larger doses of radioactive 
iodine [8]. Another way to use NIS for diagnostic purposes is by staining removed thyroid 
specimens with labeled antibodies against the symporter. This can provide valuable information 
in terms of the cancer’s aggressiveness and response to radioactive iodide [8].  
It is worth mentioning that similar iodide transport mechanisms can be found in different tissues, 
including the stomach, salivary glands, and occasionally breasts. This can explain some side 
effects of radioactive iodine such as radiation-induced sialadenitis or xerostomia in patients 
treated for thyroid cancer [8, 9].  
The next step in the synthesis of thyroid hormones is the organification of the iodide, which is 
carried out by the thyroid peroxidase (TPO) enzyme along with hydrogen peroxide. After the 
oxidation process, newly formed organic iodine iodinates the tyrosyl residues in thyroglobulin 
(Tg) [2, 9]. The whole process takes place in the opposite surface of TFCs where the apical 
membrane faces the colloid. The final stage of thyroid hormone formation is the coupling of the 
iodotyrosine molecules within thyroglobulin. Depending on the number of coupled iodine 
atoms, different types of thyroid hormone can be formed. While T4 is formed by coupling two 
molecules of diiodotyrosine (DIT), T3 is formed by coupling one molecule of DIT and one 
molecule of monoiodotyrosine (MIT). Antithyroid medications target the thyroperoxidase 
enzyme, which in turn blocks the formation of mature, end stage hormones.    
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The primary storage of thyroid hormones is the thyroid follicle colloid where the completely 
formed hormone is linked to thyroglobulin (Tg) [2, 9, 11]. Since it is one of the largest, active 
biological molecules in the human body and plays a central role in thyroid hormone synthesis 
and storage, thyroglobulin tends to have high diagnostic value in patients with different thyroid 
disorders including metastatic differentiated thyroid cancers [8]. High Tg levels indicate an 
increased probability of metastatic disease, especially in bones, lungs, and lymph nodes. 
Undetectable Tg levels combined with a negative whole body iodine scan are very reliable 
followup tests showing the absence of residual cancerous tissue [8]. 
The primary stimulator for thyroid hormone secretion is TSH which promotes proteolysis of 
thyroglobulin, followed by the release of free hormones into circulation [2, 9]. The equilibrium 
between the unbound (metabolically active) and bound (metabolically inactive) fractions of the 
released hormone is regulated by carrier proteins such as thyroxine-binding globulin (TBG), 
transthyretin (TTR), albumin, and lipoproteins [11].  
The thyroid’s growth and functional activity, starting with the formation of thyroid hormones 
and ending with their secretion, is tightly regulated by the hypothalamo-pituitary-thyroid axis. 
The primary signal comes from the hypothalamus: thyrotropin-releasing hormone (TRH) 
stimulates TSH synthesis and release from the anterior pituitary which in turn stimulates the 
growth and hormone secretion of the thyroid itself. This mechanism is widely used in treating 
thyroid cancer as chronic suppression of TSH mitogenic activity by exogenous thyroxine is 
crucial in preventing cancerous cell activity [9].   
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The second hormone produced by the thyroid gland (C cells) is calcitonin which is a 32-amino 
acid polypeptide belonging to a family of related molecules called the calcitonin gene-related 
peptides (CGRP) [5, 9]. Calcitonin is one of the compounds regulating calcium levels in the 
blood. In conditions causing elevated levels of blood calcium, C cells secrete calcitonin which 
downregulates osteoclast-mediated bone resorption and by doing so it decreases high serum 
calcium levels [5]. Calcitonin may also serve as a tumor marker in medullary thyroid carcinoma 
which is part of Sipple syndrome (MEN type 2A) and is related to RET proto-oncogene. 
 
Epidemiology (6) 
 
With 140,000 newly diagnosed cases worldwide, thyroid cancer is the most common endocrine 
tumor and accounts for 2.5% of all human cancers [17-19]. Its incidence was relatively stable 
until the early 1990s. During the last three decades the incidence of thyroid cancer has increased 
drastically all over the world [20-24]. This trend is observed on all continents except Africa 
which probably is related to insufficient detection [24]. Between 1973 and 2009 the incidence 
of thyroid cancer more than doubled worldwide including such developed countries as the U.S., 
Canada, France and Australia [17, 22]. During the last 20 years the overall incidence rate has 
gone up by more than 6% annually [22]. While 20 years ago thyroid cancer was ranked only 
14th, currently it is the 5th most common cancer in women. In Italy, it is the second most 
prevalent cancer among women in the age group below 45 [16, 24].    
Rates of thyroid cancer are rising in both genders, but due to the more dramatic pattern in 
females it is estimated that by 2019 thyroid cancer will surpass the rates of common cancers and 
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will become the third most prevalent cancer in women of all age groups and the second most 
common cancer in women younger than 45 in the U.S. [21, 25]. In 2014, there were 62,980 new 
cases of thyroid cancer in the U.S.  Every year thyroid cancer accounts for around 3.8% of all 
newly diagnosed cancer cases in the U.S.  Overall, its incidence increased from 4.9 to 14.7 per 
100,000 population in 2011. According to the Surveillance, Epidemiology, and End Results 
(SEER) program conducted in the U.S., the average annual percentage change (AAPC) for 
thyroid cancer is +5.2 in men and +5.7 in women for the 2002-2011 time interval [16]. The 
SEER database, which is a population-based cancer registry involving around 10% of the U.S. 
population, provides epidemiologic data on different characteristics of tumors as well as 
treatment approaches and survival rates [21]. It summarizes relevant epidemiologic information 
collected from 1973 to 2012. The higher incidence rate has been mostly attributable to papillary 
cancer, with only a slight increase in other histotypes [22]. Due to thyroid cancer’s indolent 
nature, the mortality rate is not as high as in other more common cancers. In 2014, estimated 
mortality from thyroid cancer was around 1,890 individuals. In comparison, the primary 
“killers” such as breast and lung cancers cause hundreds of thousands of deaths each year [20]. 
However, based on the SEER program’s results, the thyroid cancer mortality rate rose slightly 
for the 2001-2010 period with an AAPC of 0.9 [16].  In fact, the observed upshift in thyroid 
cancer mortality is not only statistically significant, it also surpasses the increase in mortality 
rate of any other cancer, except liver [26]. This increase in the mortality rate has occurred in 
spite of the introduction of better diagnostic and therapeutic measures [24]. 
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Epidemiology: Canada (6.1) 
 
Canada reflects the same trend: the overall incidence of thyroid cancer increased by 156% 
between 1991 and 2006 [27]. A study based on data from the Canadian Cancer Registry showed 
that age-adjusted incidence rates doubled between 1970-72 and 1994-96 [28]. Another study 
revealed that the rise in thyroid cancer incidence in Manitoba reached 373% from 1970-2010 
[23]. The same trend was observed in an Ontario-based retrospective study indicating that the 
incidence rate was up 146% from 1990 to 2001 [29]. In 2007, more than 4,000 Canadians were 
diagnosed with thyroid cancer, or nearly 12 cases per 100,000 population, which accounts for 
around 2.5% of all malignant tumors [30]. In 2012, the numbers were even worse as an estimated 
5,650 Canadians were diagnosed with thyroid cancer for the first time [23]. Characteristic 
features of thyroid cancer are an incidence rate that is three times higher in women than in men, 
along with the relatively young age of affected patients [30]. Around 75% of all cases are 
diagnosed before age 60, and nearly 40% of all thyroid cancers are found before the age of 45. 
With such a high incidence rate among the young population, thyroid cancer is currently ranked 
as the second most common cancer in Canadians aged 15 to 44 and is the most common cancer 
diagnosis in those aged 15 to 29 [30]. While papillary cancer is the most widespread histotype, 
composing 86% of all diagnosed cases, follicular, medullary, and anaplastic thyroid cancers 
represent 6%, 2%, and 1% respectively. Thyroid cancer has the most rapidly rising incidence 
rate in Canada. The age-standardized incidence rate (ASIR) jumped 5.7% per year in males 
(from 2.0 to 5.2 per 100,000 population) and 7.3% per year in females (from 6.8 to 17.9 per 
100,000 population) for the 1992-2007 period. The most vulnerable category in terms of the 
highest spike in ASIR was women aged 30 to 59, with an annual ASIR of 8.2% [30]. The 
increasing ASIR trend was observed in all Canadian provinces and territories over the last 16 
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years. This progression varies widely across the various provinces. In 2007, the highest ASIR 
was in Ontario (15.2 per 100,000) and the lowest were in Saskatchewan (5.2) and British 
Columbia (5.8) [30]. For the same period, the annual percentage change (APC) for Quebec was 
7.3% and the ASIR was around 11 per 100,000 population which is not much different from the 
Canadian average of 11.6 per 100,000. 
The situation is completely different when it comes to the mortality rate from thyroid cancer: it 
has remained exceptionally low and stable [23, 30]. For the 1992-2007 period, there were an 
average of 142 deaths per year in Canada with even a slight decrease (less than 1% per year) in 
the age-standardized mortality rate from 0.5 per 100,000 in 1992 to 0.4 per 100,000 in 2007 
[30]. Thyroid cancer’s low mortality rate is reflected in the five-year relative survival rate which 
is the highest of all cancers in Canada, reaching 97% for the 2001-2003 timeframe [30] and 98% 
in 2011 [23]. Increased incidence of thyroid cancer with low mortality causes increased 
proportional prevalence, with two- and five-year prevalence exceeding 9% per year from 
1999/2000 to 2008 [31]. Only liver cancer has higher prevalence (8.5%) for a 10-year duration 
[31].  
According to the Canadian Cancer Society, thyroid cancer is the 5th most common cancer in 
women and accounted for 5% of all cancers in 2015 [32]. In 2015, out of 6,300 newly diagnosed 
thyroid cancer cases, 4,800 were in women (ASIR 23.1 per 100,000) and 1,450 in men (ASIR 
6.7 per 100,000). By comparison, in 1986 the ASIR for women was 5.2 per 100,000 population 
which proves once again the tremendous spike in thyroid cancer incidence [32].  
19 
 
The Canadian Cancer Society has also indicated that Quebec is second after Ontario with around 
360 men and 1,200 women being newly diagnosed with thyroid cancer in 2015. These values 
correlate with an ASIR of 7 and 25 per 100,000 population in men and women respectively [32]. 
 
Increasing incidence hypothesis (7) 
Overdiagnosis of subclinical disease reservoir (7.1) 
 
There are multiple controversial explanations for the worldwide increase in thyroid cancer. 
Although various hypotheses have been put forward to pinpoint the principal mechanism behind 
such a dramatic upsurge in the thyroid cancer incidence rate, many authors agree that the main 
question that needs to be answered is whether the alarming increase reflects a true change in 
incidence or is simply due to the “overdiagnosis” of subclinical disease [18, 20, 22, 24, 33]. This 
distinction may have a very important clinical application in terms of prevention and 
management. For instance, a real upsurge in the incidence rate should raise concerns about 
environmental factors that may be responsible for this phenomenon. Meanwhile, the 
management approaches will have to be reviewed in case the incidence rate has been falsely 
pushed up by “overdiagnosing” a previously subclinical pool of the disease. This would help 
avoid unnecessary therapeutic interventions in an otherwise harmless, clinically insignificant 
disease [33]. 
Based on autopsies of people who died from other causes, the estimated prevalence range of 
papillary thyroid cancer varies from 3% to about 35% depending on the country and the 
pathology methods adopted to examine the specimens [16, 20, 22]. Moreover, incidental thyroid 
20 
 
cancers can be found in up to 50% of thyroid specimens removed for benign causes. These 
findings, along with the observation that the higher incidence is mostly ascribed to greater 
detection of cancers which are too small to be detected by conventional physical exams, indicate 
the existence of a large reservoir of subclinical papillary thyroid cancer. Overdiagnosis of this 
otherwise clinically insignificant reservoir of thyroid cancer can explain the “apparent” upsurge 
in the incidence rate [16].  
Many recent studies show strong evidence in favor of the hypothesis that the rising incidence is 
due to increased diagnostic scrutiny and widespread access to highly sensitive radiological 
testing [34-36]. In the last 30 years there has been a dramatic increase in the use of all kinds of 
diagnostic imaging modalities including cross-sectional imaging, with a twofold increase in CT 
scans and a threefold increase in MRI scans [33, 37]. In their study, Udelsman and Zhang 
concluded that “the epidemic of thyroid cancer” in the U.S. is largely attributable to increased 
detection. They found a statistically significant direct linear correlation between the frequency 
of cervical ultrasonography and the thyroid cancer incidence rate [34]. In another study, Zevallos 
et al. presumed that the doubling of thyroid cancer incidence within the U.S. Veterans Affairs 
healthcare system between 2000 and 2012 could be related to a nearly fivefold and sevenfold 
increases in the use of thyroid ultrasound and fine needle aspiration respectively [36]. It should 
be noted that the prevalent use of ultrasound has boosted the detection of small thyroid nodules 
which otherwise would remain undiscovered without any further diagnostic or therapeutic 
interventions [38].  
Data analysis from the National Cancer Institute’s SEER program showed that there is a large 
gender discrepancy in thyroid cancer detection. The incidence rate in women is 4 times greater 
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than in men even though the autopsy incidence of thyroid cancer is higher in men. This 
correlation is probably related to the overdiagnosing phenomenon in women [39]. Some authors 
suggest that even the age of the diagnosing physician may impact the thyroid cancer incidence 
rate, with more experienced doctors reporting fewer cases because they tend to use ultrasound 
and FNA less [40]. More aggressive approaches in terms of diagnosis and treatment, such as 
more frequent biopsies and an increase in the number and extent of surgeries especially total 
thyroidectomy [41], provide larger specimens and more opportunities for pathologists to find 
cancer [20]. The pathology guidelines for managing thyroid specimens have also changed, and 
thyroidectomy specimens are now examined in their entirety compared with the past practice of 
examining only representative sections of the specimen. More detailed examination of each 
thyroid specimen increases the chances of identifying small lesions thereby raising the incidence 
rate [20]. 
Other important factors that may have contributed to the increased incidence of thyroid cancer 
detection are access to healthcare services as well as socioeconomic status (SES) [20, 42]. 
Morris et al. showed a strong correlation between the markers of access to the healthcare system 
and the incidence of papillary thyroid cancer [22]. Countries with higher SES tend to have higher 
rates of screening procedures with a subsequent increase in thyroid cancer detection. The 
positive association between thyroid cancer and various socioeconomic indicators, such as high 
levels of income, education, and white-collar employment, would seem to indicate an increased 
screening effect [22, 24]. 
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Arguments in favor of a true increase in thyroid cancer incidence (7.2) 
 
Although most studies agree that the more widespread application of highly sensitive diagnostic 
modalities has greatly contributed to the detection of a previously “hidden” pool of subclinical 
disease, it is impossible to ignore the evidence indicating that such an upsurge in thyroid cancer 
incidence cannot be explained solely by the overdiagnosis phenomenon and that there must be 
other factors causing a true rise in the number of thyroid cancer cases [16, 20, 24].   
The main argument against the overdiagnosis hypothesis is the stable or even decreasing 
incidence of other types of cancers diagnosed with highly specialized imaging techniques and 
diagnostic biomarkers [16]. According to data from the SEER registry, the rates of some 
common cancers, such as prostate, colorectal, and breast cancer, have dropped while the 
incidence rate of thyroid cancer increased by as much as 60% for the period of observation from 
2002 to 2011.  
Assuming that improved detection is the principal mechanism of increased incidence, then the 
diagnosis and treatment of early-stage, small tumors should be accompanied by a significant 
decrease in larger, more advanced tumors [24]. Although the upsurge in the detection rate for 
small thyroid tumors (≤1 cm) certainly surpasses the rate for larger, more advanced tumors (≥4 
cm), many studies have shown a significant increases in thyroid cancer in all size categories [16, 
17, 20, 33]. In their recent study, Malone et al. demonstrated that 38% of large thyroid cancers 
(≥4 cm) are found incidentally on imaging studies done for other reasons [43]. Since it seems 
very unlikely that 38% of all large tumors were being missed in the past, a real increase in the 
incidence rate could be the reason.  
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Another interesting observation is related to the histotypes of thyroid cancer. While improved 
detection would affect all histotypes, the rise in incidence is, in fact, almost exclusively due to 
papillary thyroid cancer (PTC) [17, 24].  
Moreover, in their study, Cramer et al. state that “improved detection techniques may explain 
the 8.0%/year difference between the increase in microPTC compared with the average increase 
in neoplasms larger than 1 cm; however, changes in the methods of detection cannot explain the 
overall increase in all sizes of PTC” [17]. 
If all these hypotheses and studies are correct, there must be some underlying driving forces 
which could explain this profound increase in thyroid cancer. 
 
Risk factors causing a true increase in thyroid cancer incidence (7.3) 
 
Exposure to ionizing radiation is an extensively studied and well-documented risk factor for 
thyroid cancer due to the thyroid’s ability to concentrate iodine and the relatively higher 
irradiation because of its localization [16, 20, 24, 33]. The mechanisms behind this phenomenon 
are DNA strand breakages, the development of somatic mutations, chromosomal 
rearrangements, and intra-chromosomal inversions causing RET proto-oncogene to fuse with 
other genes such as H4 or ELE 1 [20, 33, 44]. Once exposed to ionizing radiation, young subjects 
(<20 y/o) have a higher probability of developing thyroid cancer due to greater radiosensitivity.  
During the last 20 years, the lifetime dose of ionizing radiation for many U.S. residents has 
doubled as a result of medical and dental diagnostic procedures [20, 24, 33]. Although CT scans 
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account for only 15% of all radiological diagnostic interventions, they are the source of more 
than half of the radiation doses that U.S. residents are exposed to [24]. Some studies conducted 
in pediatric populations showed a weak but nonnegligible correlation between the risk of thyroid 
malignancies and CT scan exposure. Moreover, there is an inverse correlation between the risk 
of thyroid cancer and the age at exposure. Children aged <5 years have the highest risk and there 
is a significant decline in risk after the age of 20 [33, 45]. Nevertheless, the appreciable increase 
in thyroid cancer incidence cannot be ascribed solely to CT scans because most CT scans are 
performed in patients aged >50. Another major source of irradiation is nuclear medicine where 
radioactive iodine has been widely used recently for both diagnostic and therapeutic purposes 
in different thyroid diseases [24]. Diets containing supplemental iodine are another potential 
risk factor for thyroid cancer as they interfere with iodine organification and thyroid hormone 
synthesis [24]. Another possible mechanism is the increased incidence and severity of chronic 
thyroid conditions such as chronic lymphocytic  thyroiditis and autoimmune thyroiditis [16]. 
Enviromental pollutants, such as asbestos, benzene, formaldehyde, pesticides, bisphenol A 
(BPA), polychlorinated biphenyls (PCBs), and polyhalogenated aromatic hydrocarbons 
(PHAHs), may also contribute as both genotoxic and nongenotoxic carcinogens [24]. In 
addition, chronic metabolic conditions, such as diabetes and obesity-related metabolic disorders, 
are among the proposed risk factors related to the higher incidence of thyroid cancer [20, 33]. 
Those conditions lead to low grade inflammation triggered by alterations in adipokines. This 
occurs along with increased circulating leptin and an adiponectin deficiency which is 
independently and inversely associated with thyroid cancer risk [46]. All these metabolic 
changes are linked to higher activity in the mitogen-activated protein kinase pathway which has 
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a crucial role in carcinogenesis by activating mitogenesis [33, 46, 47]. Other potential risk 
factors, including estrogen exposure and dietary nitrates, still need to be investigated since there 
is a lack of conclusive data in the literature [20, 33]. 
Overall, the reasons behind the worldwide increase in thyroid cancer are still unclear. Most 
likely, the observed exponential upsurge has a multifactorial etiology. Certainly, the increased 
detection rate can partly explain the phenomenon but, at the same time, there is strong evidence 
indicating a true increase in thyroid cancer incidence. In summary, further studies are warranted 
in order to investigate the real reasons and determine the potential carcinogens and their 
mechanisms of action [24].  
Histologic classification (8) 
 
Based on their cellular origin, characteristics, and prognosis, thyroid cancers are classified into 
several histological types and subtypes. Thyroid cancers are mostly epithelial tumors originating 
from thyroid follicular cells (TFCs) and parafollicular cells (C cells) or from nonepithelial 
stromal elements [48]. On the basis of architectural, cytologic, and histogenetic features, the 
World Health Organization (WHO) classifies primary thyroid tumors into epithelial or 
nonepithelial and benign or malignant categories. According to the same classification, 
lymphomas and miscellaneous tumors are defined as separate groups [48-51].  
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Papillary thyroid carcinoma (PTC) (8.1) 
 
Papillary thyroid carcinoma (PTC) is the most common differentiated carcinoma, accounting 
for 80-90% of all primary thyroid malignancies [9, 48, 50]. Generally, papillary carcinomas are 
indolent, slowly growing tumors. Women aged 25-45 have a three times higher risk of 
developing PTC [8]. Because of the carcinoma’s indolent nature, most cases have an excellent 
prognosis but in up to 10% of cases recurrent disease may occur in the form of cervical lymph 
node metastasis and/or distal metastasis [48, 50]. The main mode of PTC spreading is via the 
lymphatic system. Dispersion of cancerous cells within the thyroid may lead to “multifocal” 
disease and cervical node metastasis. It has been estimated that in over 50% of cases, PTCs have 
nodal metastasis at initial diagnosis [48, 50]. Since venous invasion rarely occurs, metastasis 
outside the neck is unusual [52]. In 5-7% of cases, PTC may cause distant metastasis in lungs 
and bone [52]. PTC’s tendency to spread locally in the neck may cause tracheal compression 
and involve the recurrent laryngeal nerve [5]. Although most PTC show a papillary growth 
pattern, the main distinguishing feature is malignant cytologic (nuclear) changes which are 
important diagnostic hallmarks [11, 50, 52]. The typical nuclear appearance of PTC includes 
enlargement, hypochromasia, intranuclear cytoplasmic inclusions, nuclear grooves, and distinct 
nucleoli [11]. The PTC nuclei have also been described as clear, ground glass or “Orphan-Annie 
eyed” [50, 52]. Psammoma bodies, which are another microscopic characteristic of PTC, are 
laminated calcifications that may occur in about 40% of cases [9, 11, 52]. The psammoma bodies 
are formed when calcium is deposited on the dying cells after infarction of the papillae. Another 
theory relies on the intracellular accumulation of calcium by tumor cells which later leads to 
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their death and the calcium’s release. Further  deposition of free calcium leads to lamellation 
[52].  
Microscopically, papillary carcinoma has multiple histotypes, the most important of which are 
papillary microcarcinoma (PMC), follicular variant, tall cell variant, and diffuse sclerosing type 
[49, 52].  
According to the World Health Organization (WHO), the term papillary microcarcinoma refers 
to thyroid cancer measuring 1 cm or less in diameter [53]. According to the American Thyroid 
Association, PMC detection accounts for almost 50% of the thyroid cancers diagnosed in the 
past three decades. The incidental detection of PMC in the thyroid gland is a frequent finding in 
autopsies and may indicate the indolent nature of this tumor without having any clinical 
relevance [53]. However, PMCs may lead to lymph-node metastasis in the central and lateral 
compartments of the neck [54]. Despite the incidence of locally  metastatic disease, the 
prognosis for PMC is excellent and 10 year mortality rates in patients with this tumor are less 
than 1% according to the American Thyroid Association [54].  
The follicular variant of PTC (FV-PTC) is one of the most common subtypes among all PTC 
histotypes, accounting for up to 41% of all PTC cases [55]. Although FV-PTC contains a mixed 
histology of both PTC and FTC, microscopically its architecture is predominantly follicular 
[55]. Despite some unique clinical behavior, FV-PTC seems to be quite a distinctive entity, 
sharing clinical features with both PTC and FTC. Having more favorable clinicopathologic 
features and a better tumor risk group profile does not impact the long-term outcome of FV-
PTC, which is similar to that of conventional PTC [48, 56]. 
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The diffuse sclerosing variant of PTC (DSVPTC) is an unusual variant, with prevalence ranging 
from 0.7-6.6% of all PTCs. A macroscopic feature of DSVPTC is the extensive involvement of 
the thyroid gland without forming a dominant mass [57]. Its hallmark on microscopic 
examination is the extensive fibrosis, squamous metaplasia and numerous psammoma bodies. 
Since DSVPTC has a higher incidence of lymph node metastasis at presentation than 
conventional PTC, along with a distant metastasis rate of around 5%, aggressive treatment 
protocols are required in managing DSVPTC [57]. Nevertheless, cancer recurrence and cancer-
related mortality have been reported at 14% and 3% respectively [57]. 
The tall cell variant of PTC, which has 10% prevalence and a 10-year mortality rate of up to 
25%, is the most common aggressive variant of PTC [50, 58]. Microscopically, tall cells are 
twice as tall as their width and should represent at least half of the papillary carcinoma cells 
[50]. This variant has a high prevalence among patients with radioactive iodine refractory 
disease and is associated with a high rate of B-RAF mutations, making the latter a potential 
target in terms of treatment strategies [58]. 
 
 
 
Follicular thyroid carcinoma (FTC) (8.2) 
 
Follicular thyroid carcinoma (FTC) is the second most common malignant neoplasm arising 
from epithelial cells. It accounts for 5-10% of thyroid cancers in non-iodine deficient areas and 
ranges up to 30-40% in iodine deficient areas [48]. Because it is difficult to distinguish follicular 
carcinoma from follicular adenoma based on the results of fine needle aspiration (FNA), the 
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term “follicular neoplasm” is used for these tumors. Other methods, such as 
immunohistochemistry, morphometry, cytogenetic, and oncogen markers, have not provided 
reliable information regarding the distinction between follicular adenoma and follicular cancer 
on FNA [48]. Excisional biopsy (hemithyroidectomy) may be warranted in order to establish 
the precise histologic diagnosis on the basis of capsular and vascular invasion which helps 
discriminate between benign and malignant lesions [6]. On microscopic examination, follicular 
carcinoma is usually composed of microfollicles (minimal amount of colloid within the small 
follicles) or solid nests of tumor [8]. Depending on the degree of invasiveness, there are two 
major groups of follicular carcinomas: minimally invasive and widely invasive [48]. Follicular 
cells may invade either the tumor capsule and/or the blood vessels, with vascular invasion 
having a worse prognosis. Other recognized risk factors, such as age >45, gender, extrathyroid 
invasion, greater tumor size, and the presence of distant metastasis at presentation, are also 
associated with poorer prognosis [32]. Nevertheless, metastases to cervical lymph nodes are rare 
and are often accompanied by direct extrathyroidal extension of the cancer [9]. 
 
 
 
Hurthle cell carcinoma (8.3) 
 
One of the variants of follicular carcinoma is Hurthle cell carcinoma which is composed 
predominantly (>75%) of oncocytic cells and is thought to have a worse prognosis than the usual 
follicular carcinoma [48, 50]. The benign variant of Hurthle cell lesions represented by Hurthle 
cell adenoma is generally indistinguishable from the malignant variant based only on the results 
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of cytological analysis. Thus, once a Hurthle cell lesion is detected by FNA, an excision biopsy 
may be indicated for further histological analysis [5].  Metastasis to cervical lymph nodes in 
Hurthle cell carcinoma is more common compared to the usual follicular carcinoma [9]. 
 
 
 
Poorly differentiated thyroid carcinoma (PDTC) (8.4) 
 
Poorly differentiated thyroid carcinoma (PDTC) characterizes a heterogeneous group of 
malignant neoplasms. It was recognized as a distinct pathologic entity by the WHO in 2004 [59]. 
The macroscopic hallmarks of PDTC are large (>5 cm in diameter), solid, unencapsulated, 
nodular or multinodular, gray-white tumors which are likely to penetrate perithyroidal tissues. 
On microscopic examination, these tumors represent a trabecular, solid or insular growth pattern 
[48]. Due to its heterogeneity, PDTC has different biologic behavior and various histologic 
patterns of growth. Although PDTC accounts for only 1-15% of all thyroid cancers, it is the 
main cause of death from “nonanaplastic follicular cell-derived thyroid cancer” [59, 60]. 
 
Medullary thyroid cancer (MTC) (8.5) 
 
Medullary thyroid cancer (MTC) is a neuroendocrine tumor of the thyroid gland’s parafollicular 
or C cells and it accounts for up to 10% of all malignant thyroid tumors [48]. Although 
approximately 80% of all MTCs are sporadic cases, there are also some hereditary cases 
resulting from RET proto-oncogene mutation which is the underlying defect in Multiple 
Endocrine Neoplasia type 2 (MEN2) [61]. Despite MTC’s morphological diversity, the 
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particular type of histology does not seem to influence the disease’s course [62]. The primary 
manifestation of sporadic MTC in most cases (75-95%) is a solitary nodule, usually located in 
the upper portion of the thyroid lobe [61, 63, 64]. In the majority of cases, the MTC has already 
metastasized at presentation, with 50% of patients having clinically detectable cervical lymph 
nodes, up to 15% having upper aerodigestive tract compression signs, and 5% having distal 
metastatic disease [63]. A characteristic feature of MTC is the production of calcitonin which 
can serve as a tumor marker because its concentration usually correlates with tumor mass and is 
almost always abnormally elevated in patients with a palpable tumor [63]. The MTC cells are 
also capable of secreting carcinoembryonic antigen (CEA) which may indicate advanced disease 
if levels are abnormally high [65]. 
 
 
Anaplastic thyroid carcinoma (ATC) (8.6) 
 
Anaplastic thyroid carcinoma (ATC) is an extremely aggressive malignant thyroid tumor which 
accounts for less than 2% of all thyroid malignancies [66, 67]. Compared to differentiated 
thyroid cancers, ATC’s disease-specific mortality rate surpasses 90%, with an average survival 
duration of 6 months after diagnosis [66]. Having a mean age of 65 at initial presentation, most 
patients with ATC are older than those with differentiated thyroid carcinoma [67].  
The major etiologic factors of ATC are pre-existing thyroid diseases or other types of thyroid 
cancer such as PTC, FTC, or poorly differentiated carcinoma. This observation supports the 
theory that ATC develops from more differentiated tumors following the dedifferentiating 
events [68]. This hypothesis might be supported by the fact that both well differentiated thyroid 
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cancers and ATC have the same underlying molecular development mechanism. In both cases, 
mutations in BRAF and RAS play a central role in the early events of the progression pathway. 
Although ATC has multiple histopathological features, there is no evidence showing the impact 
of a particular histotype on the prognosis [66]. Around 90% of patients have regional or distant 
metastasis at the time of initial presentation, with lungs being the most common site of distal 
metastasis [69, 70]. 
 
 
Thyroid cancer staging (9) 
 
According to the American Cancer Society, the TNM system adopted by the American Joint 
Committee on Cancer (AJCC) is the most frequently used system to describe thyroid cancer 
stages. Based on three key parameters, the TNM system indicates the size of the primary tumor 
(T), describes the extent of metastatic disease to the regional lymph nodes (N) and specifies 
whether there are distant metastases to other organs (M).  
Primary tumors (T) for nonanaplastic thyroid cancer might be subdivided into several 
subcategories, the first being Tx where the tumor cannot be assessed due to missing information 
and the most advanced being T4b where the tumor has invaded prevertebral fascia or encased 
the carotid artery or mediastinal vessels [71, 72]. All anaplastic thyroid carcinomas are 
considered T4 tumors at initial diagnosis, with T4a having only intrathyroidal expansion 
(surgically resectable) and T4b growing outside the thyroid gland (surgically unresectable) [71, 
72].  
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The N parameter describes the metastasis into the regional lymph nodes, consisting of the central 
compartment, lateral cervical, and upper mediastinal lymph nodes. This parameter is also 
divided into several subcategories, with the most advanced being N1b which is associated with 
unilateral, bilateral, contralateral cervical, or superior mediastinal lymph node metastasis [71]. 
There are only three subcategories for M when evaluating distant metastasis. M1 indicates that 
the cancer has spread to distant lymph nodes and internal organs [71]. 
After the TNM values have been determined (table I, page 54), the combined results are used to 
assign the stage (ranging from I to IV). Differentiated thyroid cancers (PTC and FTC) are further 
grouped into stages in a way that the patient’s age is taken into consideration as a dichotomous 
variable. The cutoff value is age 45 and all patients below that age are either Stage I (no distant 
metastases) or Stage II (distant metastases present), which means they should have an excellent 
prognosis [11, 71, 72].  
In contrast to PTC and FTC, age is not a factor in MTC staging, and all ATCs are considered 
Stage IV tumors, reflecting the poor prognosis for this type of cancer [71, 72]. 
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Molecular Pathogenesis (10) 
 
Several types of genetic alterations and epigenetic changes have been shown to play a 
fundamental role in the tumorigenesis of different variants of thyroid cancer [48, 73, 74]. An 
understanding of the pathways, such as gene mutation, aberrant gene methylation, and gene 
translocation, can open up new perspectives in terms of molecular diagnostics, treatment, and 
prognosis prediction [74]. 
One of the most common pathogenetic mutations of differentiated thyroid carcinoma (DTC) is 
the point missense mutation in exon 15 of BRAF which occurs in around 45% of sporadic PTCs 
[50, 73, 74]. This mutation is generated when glutamic acid is replaced by the amino acid valine 
at residue position 600. It leads to the expression of the BRAF-V600 mutant protein, causing 
constitutive activation of serine/threonine kinase [73, 74]. Over 90% of BRAF alterations are 
due to a V600 mutation. The most common subtype of PTC carrying a BRAF mutation is the 
tall cell variant (77%), with FVPTC having the lowest percentage (12%) of this particular 
mutation [50, 73]. 
Several studies have observed a correlation between BRAF-V600 mutation and the 
clinicopathological features of PTC [75]. BRAF mutation is more common in older patients and 
is associated with extrathyroidal invasion, advanced stages, and poorer clinical outcomes 
including higher recurrence rates and refractoriness to radioiodine treatment since BRAF 
mutation is responsible for suppressing the sodium/iodide symporter (NIS) [50, 73]. 
Rat sarcoma oncogene (RAS) mutations are second in prevalence after BRAF mutations. There 
are three RAS isoforms: H-RAS, K-RAS, and N-RAS [50, 73, 74]. The most frequent RAS 
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mutations linked with thyroid cancer are the point mutations in codon 61 of H-RAS and N-RAS. 
These mutations cause RAS to lose its intrinsic GTPase activity, which means that RAS is in a 
permanent GDP-bound active state [73, 74]. Although RAS has a classic dual stimulator impact 
on the MAPK and PI3K–AKT pathways, in tumorigenesis RAS activates the PI3K–AKT 
pathway instead [74]. Despite the fact that RAS mutation is relatively rare (0-20%) in 
conventional PTC, approximately half of FTCs and FVPTCs may carry RAS mutations. In 
addition, 20% of follicular adenomas may harbor a RAS mutation, suggesting that RAS 
mutation is an early event in tumorigenesis [50]. PTCs carrying RAS mutations are predisposed 
to a more benign disease course with a lower rate of lymph node metastasis and greater 
likelihood of encapsulation [73]. 
Chromosomal rearrangement of RET proto-oncogene is an example of the gene translocations 
which were first observed in PTC, thus, it is called RET/PTC. The rearranged RET/PTC is 
located on chromosome 10q11-12 and encodes a transmembrane receptor RTK [73, 74]. 
Although there are more than 10 types of RET–PTC translocation, RET/PTC1 and RET/PTC3 
are responsible for most of the rearrangements found in PTC [73, 74]. These rearrangements 
cause constitutive activation of several downstream pathways including MAPK and PI3K-AKT 
[50]. It is worth noting that RET/PTC chromosomal rearrangements are observed in 15-45% of 
conventional PTCs and 80% of radiation induced PTCs [50, 76].  
The balanced translocation between chromosomes 2 and 3 results in the PAX8/PPAR fusion 
oncogene which is detected in 36.5% of FTCs (from 11% to 63%), 9.5% of follicular adenomas, 
and 13.2% of FVPTCs. This is the most common genetic abnormality involved in FTC [77].  
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Epigenetic modulations, such as DNA methylation, histone deacetylation, and chromatin 
remodeling, have been implicated in DTC tumorigenesis as well [75]. 
The mechanism of MTC molecular pathogenesis is also associated with RET proto-oncogene 
which is detected in almost all patients with hereditary MTC and in 30-50% of sporadic cases. 
MTC aggressiveness can be predicted by the presence of certain RET mutations along with 
designated levels of calcitonin and carcinoembryonic antigen (CEA). Low calcitonin levels in 
combination with high CEA levels or a rapid CEA/calcitonin doubling time indicates a poorer 
prognosis and the disease’s progression [78].  
In a clinical setting, stratifying patients with germline RET mutations into specific risk groups 
may help target the patients with higher risk of malignant transformation. In those patients, a 
prophylactic thyroidectomy represents the best chance of curing the familial MTC [78]. 
The most common mutations reported in ATC are p53, RAS, and BRAF [79]. Overall, the p53 
tumor suppressor gene is the most frequently affected gene in human cancer. It is assumed that 
p53 genetic alterations are late events in the thyroid tumorigenesis cycle and might be linked to 
a poor prognosis [48]. 
 
Diagnostic modalities in managing DTC (11) 
 
According to the American Thyroid Association Management Guidelines [80], the main goals 
of initial therapy in patients with DTC are to improve overall and disease-specific survival, 
diminish the risk of persistent/recurrent disease and associated morbidity, and provide the 
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necessary conditions for accurate disease staging and risk stratification. At the same time, 
precautions should be taken in order to minimize treatment-related morbidity and unnecessary 
therapeutic interventions. To reach those goals, the American Thyroid Association strongly 
recommends performing preoperative staging with diagnostic imaging that may or may not 
include laboratory tests [80]. The frequency of micrometastasis is high but it does not have as 
much clinical significance as macrometastasis. Preoperative ultrasonography of the central and 
lateral compartments may identify abnormal lymph nodes in up to 35% of patients [81]. These 
ultrasound (U/S) findings may alter the planned surgical approach in up to 20% of cases by 
facilitating complete resection of the disease and potentially minimizing locoregional recurrence 
[82, 83]. However, preoperative U/S identifies only 50% of the lymph nodes affected in the 
central compartment because the overlying thyroid gland does not allow adequate visualization 
[84]. Although there is no single sonographic feature with adequate sensitivity and specificity, 
evaluating a combination of such characteristics as size, loss of fatty hilum, shape, echogenicity, 
cystic changes, calcifications, margins, compressibility and peripheral vascularity may help 
when making decisions about further managing suspicious lymph nodes [80, 85]. Among all 
those features, microcalcifications have the highest specificity. Any lymph node with 
microcalcification should therefore be considered abnormal [84]. In their study, Chung et al. 
showed an exponential increase of metastasis rate associated with the increased number of 
suspicious sonographic features. Most notably, in the presence of 4 suspicious features on U/S, 
the rate of metastasis was 100% [86]. 
The location of suspicious lymph nodes on U/S may also be of some benefit in decision making 
as malignant lymph nodes are more likely in levels III, IV, and VI [87]. 
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One obvious advantage of U/S compared with other imaging modalities is the possibility of 
proceeding with U/S guided fine needle aspiration (FNA) for sonographically suspicious lymph 
nodes [88].  
FNA for the cytologic evaluation of thyroid cancer was first used by Martin and Ellis at New 
York Memorial Hospital for Cancer and Allied Diseases in 1930 [89]. Undefined thyroid 
nodules are a common clinical problem as 4-7% of the U.S. adult population may have palpable 
thyroid nodules [89]. The evidence shows that the probability of developing thyroid cancer from 
a clinically solitary thyroid nodule or a multinodular goiter is about 5% in non-endemic areas 
[89]. The principal indications for FNA are therefore thyroid nodules or cervical lymph nodes 
that are sonographically suspicious for thyroid cancer. More widespread use of this procedure 
has reduced the number of diagnostic thyroid surgeries for suspicious thyroid nodules by 60-
85% [89]. The recommendations known as the Bethesda System for Reporting Thyroid 
Cytopathology were adopted as a way to report thyroid nodule FNA cytology. The system 
consists of the following diagnostic categories: nondiagnostic or unsatisfactory, benign, atypia 
of undetermined significance or follicular lesion of undetermined significance, follicular 
neoplasm or suspicious for a follicular neoplasm, suspicious for malignancy, malignant. The 
cancer risk estimate within each of the 6 categories is determined based on literature review and 
expert opinion [80].  
Although it may be difficult to interpret results in patients with an intact thyroid gland, adding 
FNA-Tg (thyroglobulin) washout to the diagnostic workup of suspicious cervical lymph nodes 
may be of some benefit in selected patients [80]. A cutoff value of 1 ng/ml for FNA-Tg provides 
100% sensitivity, 96.2% specificity, and 97.2% positive predictive value [90]. FNA-Tg washout 
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may be especially useful in cases where FNA is not diagnostic due to inadequate cytologic 
evaluation, cystic degeneration of the lymph node, or equivocal results from cytologic and 
sonographic evaluations. In those cases, adding FNA-Tg may help overcome the limitations of 
FNA because combining 1 or 2 suspicious U/S features with FNA-Tg may significantly increase 
sensitivity [86].  
Other imaging modalities such as CT and MRI with contrast can be used in addition to U/S in 
advanced disease cases where there are invasive tumors or clinically apparent involvement of 
multiple LNs. Ahn et al. showed that although U/S has very high accuracy when used for per 
patient analysis, CT’s even higher accuracy in terms of per level analysis may enable it to play 
an adjunctive role in decision making about surgical extent in selected patients with thyroid 
cancer [91]. Another study showed that preoperative mapping with combined U/S and CT was 
significantly superior to U/S alone in primary and revision patients both in the central and lateral 
compartments [92]. MRI has relatively low sensitivity (30-40%) for detecting cervical lymph 
node metastasis [80].   
 
Preoperative ultrasound cervical mapping (12) 
 
There is an accepted opinion that although clinically apparent and/or palpable LNs should be 
removed, very small cancerous LNs do not need to be resected as the subsequent radioiodine 
therapy can resolve the issue in those groups of patients. Other patient groups may harbor 
nonpalpable metastasis located in both the central and lateral neck compartments. In those 
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patient groups, U/S is an indispensable tool for detecting and managing occult metastasis  [83, 
93].  
In DTC, the incidence of cervical LN metastasis at the time of diagnosis is about 20-50%, and 
the incidence of micrometastases may approach 90% depending on the detection method used 
[91, 93]. Although there is some controversy regarding the prognostic impact of cervical LN 
involvement, the evidence shows that patients with cervical LN metastases at initial presentation 
tend to have more locoregional recurrence than those without LN involvement [93-95].The  
locoregional recurrence rate of DTC ranges between 5% and 30%  within 10 years of initial 
diagnosis  [82, 96]. However, given the indolent nature of  DTC, 5 and 10 years survival rates 
are 95% and 90% respectively [97]. Despite a high overall survival rate, local P/R disease caused 
by LN metastasis continues to present management challenges especially in the central 
compartment. In contrast to the lateral compartment, clinical and radiological detection of 
central neck nodal metastasis is not sufficiently reliable at pre-operative assessment. 
Prophylactic central neck dissection (pCND) is performed in order to reduce the risk of P/R 
disease in the central compartment [98]. Nevertheless, the role of pCND remains controversial 
in managing DTC due to a lack of prospective randomized controlled studies [80]. In their 
retrospective study, Barczynski et al. showed statistically significant improvement in the 
survival rate of a group of patients who underwent total thyroidectomy (TT) with pCND versus 
TT alone (98% and 92.5% respectively over the 10-year period) [99]. The same study also 
showed a significant reduction in the 10-year local recurrence rate of TT with pCND versus TT 
alone [99]. However, different meta-analysis did not definitively show any significant risk 
reduction in the local recurrence rates of TT with pCND in comparison to TT alone [100].  
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In MTC, LN involvement at the time of initial diagnosis ranges from 35% to 50% [101]. Due to 
the more aggressive course of the disease, the locoregional recurrence rate of MTC is about 45% 
by the 10 years followup point[102]. However, the overall prognosis for patients with MTC is 
good because the 10 years survival rate ranges from 75% to 85%[101]. 
 As indicated by the data, in many cases patients may have undetected macroscopic LN 
metastases at the time of initial surgery. Detecting and resecting these LNs may prevent 
subsequent reoperation due to recurrent disease and may reduce the risk of postoperative 
morbidity [82]. Therefore, it is crucial to detect  metastatic LNs before the surgery because 
accurate preoperative mapping of the cervical nodal levels is essential for adequate surgical 
planning, which in turn may reduce the risk of postsurgical complications from repeated surgery 
[91]. U/S is currently the preferred imaging modality for preoperative detection and assessment 
of cervical nodal metastases [91]. It has several advantages as it is radiation-free, easy to 
perform, and is widely available [88]. At the same time, this modality has some drawbacks: it is 
subjective, operator dependent, and subject to anatomical limitation of the examination field 
[91]. 
Nevertheless, some authors point out that positive preoperative U/S findings for LN metastases 
may indicate a more aggressive course for the disease which will necessitate additional surgical 
intervention in the future [103] .  
Considering the relevance of this imaging modality, we decided to evaluate the qualitative and 
quantitative reliability of preoperative U/S lymph node detection based on cervical nodal levels, 
which is otherwise known as “ultrasound cervical mapping.”  
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Abstract 
 
Background 
 
Cervical lymph node involvement in thyroid cancer is associated with locoregional recurrence 
and decreased disease-free survival. Preoperative lymph node mapping helps in planning 
surgery for neck dissection and improves patient outcomes. The aim of this study was to perform 
a qualitative and quantitative analysis of ultrasound mapping for thyroid cancer and evaluate the 
significance of this exam in terms of identifying the group of patients who would benefit most 
from subsequent surgical dissection. 
Methods 
 
Retrospective review of 263 patients who underwent thyroid surgery between 2009 and 2013 
was performed. The positive predictive values of ultrasound mapping of both the lateral and 
central compartments together and the lateral or central compartment individually were 
calculated. A quantitative analysis was performed by comparing the number of positive lymph 
nodes at ultrasound imaging with histopathologic evaluation. 
Results 
 
136 cases in 120 patients met the inclusion criteria for ultrasound mapping analysis.   The 
positive predictive values (PPV) were: lateral and central compartments PPV=83.82 (95% CI 
0.76-0.89), lateral compartment PPV=85.39% (95% CI 0.76-0.91), central compartment 
PPV=80.48% (95% CI 0.7-0.87). When comparing the positive lymph nodes at ultrasound 
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imaging with histopathologic evaluation using the chi-square test, the result was X2=10.33 
(p=0.006). 
Conclusion 
 
This single-institution study indicated that preoperative ultrasound mapping is an accurate 
imaging procedure for predicting lymphatic spread in differentiated and medullary thyroid 
cancer. Ultrasound mapping can be used as an efficient tool for surgical planning and prognosis 
determination, as well as for identifying the group of patients who would benefit most from 
subsequent surgical intervention. 
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Introduction 
 
Differentiated thyroid carcinomas are the most common types of thyroid malignancies. Papillary 
carcinoma (PTC) accounts for approximately 80% of all thyroid neoplasms [104, 105]. PTC has 
shown a permanent increase in its incidence [106], with the fastest increase in women [104], 
making it now the sixth most common cancer among women. There are several major risk 
factors for developing PTC, such as exposure to ionizing radiation and a family history of 
thyroid cancer. PTC is also associated with oncogenes mutations such as BRAF, RET/PTC, 
RAS and TRK [104]. 
Despite a high survival rate with 5- and 10-year overall survival of 90% and 95%, respectively 
[97], about 20%-50% of patients require additional treatments for lymph node (LN) metastasis 
[93, 97, 107]. In 80%-90% of patients, micrometastasis can be found in meticulous bilateral 
neck dissection [93, 104, 108]. Although cervical LN metastasis has almost no impact on short-
term survival, it greatly affects long-term survival as a major risk factor for locoregional tumor 
recurrence [97]. LN metastasis is related to several predisposing risk factors such as male 
gender, age over 45, tumor size more than 1 cm, and lymphovascular and extrathyroidal 
invasions [109]. Moreover, PTC located in the upper neck was shown to present a higher rate 
of lateral neck metastasis than lower neck PTC [109]. 
Despite an increased rate of recurrence in patients with PTC and LN metastasis, there is no 
evidence that radical neck or routine central compartment dissection can improve disease-free 
survival, particularly in papillary thyroid microcarcinomas measuring less than 10 mm [110]. 
Since neck dissection is associated with such complications as hypocalcaemia, recurrent 
laryngeal nerve palsy, hematoma, chyle leakage and spinal accessory nerve dysfunction, the 
indications for surgical intervention should be thoroughly investigated [111, 112].  
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LN involvement can be detected by physical examination, with a sensitivity as low as 15%-30% 
[109, 113], while neck imaging is highly efficient, in particular high-resolution ultrasound (U/S) 
which is able to detect nodules as small as 5 mm.  CT scans can also be used for staging LN in 
thyroid carcinoma. Although most studies agreed that US is the first choice [83, 114-116] some 
investigators found comparable sensitivity with CT and even slightly higher than US for the 
central compartment [91, 117]. In those studies, it is interesting to observe that the sensitivity of 
the US is lower (under 80 %) than what was previously reported.  CT necessitates the injection 
of a high quantity of iodine contrast which could interfere in the follow up investigation and 
treatment of the patient.  Indeed after receiving iodine contrast, the patient must wait between 
3-4 months before being able to receive radioactive-iodine treatment or a thyroid iodine uptake 
scan.  It is important to be aware of the patient therapy and coordinate the CT with the medical 
team.  This is clearly a disadvantage for this modality.  Using U/S also gives the opportunity to 
practice FNA (fine needle aspiration) on LN that are undetermined and influence the extent of 
the dissection. 
An U/S-based preoperative evaluation of the primary tumor’s extent as well as LN involvement 
has become an essential procedure, which can modify the overall surgical approach in up to 40% 
of cases [85, 110]. This approach is recommended in the guidelines of the American Thyroid 
Association [118].    
The aim of this study is to evaluate the diagnostic reliability of preoperative U/S mapping of 
thyroid cancers in our institution by calculating the positive predictive value (PPV) of the test 
and trying to determine whether there is a quantitative association between U/S mapping and 
pathological analysis. The interpretation of such an association may help to target the group of 
patients who would benefit most from the subsequent surgical procedure and at the same time 
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help avoid unproductive surgical dissection in patients with minimal risk of disease recurrence. 
To our knowledge, no study has been done to evaluate the existence of such a quantitative 
association between cervical LN mapping and pathological results. 
 
Materials and methods  
 
The medical records of 263 patients who underwent surgery for thyroid cancer at the Centre 
hospitalier de l’Université de Montréal (CHUM) between 2009 and 2013 were retrospectively 
reviewed. The only exclusion criterion was the absence of U/S mapping. Electronic institutional 
database and Microsoft Access software were used for data collection. Surgeries were performed 
by nine surgeons (one endocrine surgeon and eight otorhinolaryngologists). Ten radiologists 
were involved in the study but more than 80% of cases were examined by one radiologist with 
advanced skills in U/S mapping of thyroid cancer. An U/S system equipped with a high-
resolution (13 MHz) linear probe was used. Parameters including operative procedures, 
pathological analyses and mapping results according to neck compartments were collected. 
 
For the purpose of quantitative analysis, patients were divided into two groups based on the 
number of suspicious LNs at U/S mapping (group A: 1 or 2 LNs; group B: 3 or more LNs). 
Concerning the histopathological results, three groups were created according to the number of 
positive LNs (group 1: 0 LNs; group 2: 1 or 2 LNs; group 3: 3 or more LNs). The LN location 
in the neck was divided into central (CC) and lateral compartments (LC). CC is defined as the 
space between the medial margins of bilateral carotid arteries, corresponding to level VI, while 
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LC extends from the carotid arteries to the medial border of the trapezius muscle and involves 
levels II, III, IV and V, according to the definitions of the American Head and Neck Society and 
the American Academy of Otolaryngology – Head and Neck Surgery [109, 119, 120].  
 
The imaging suspicion of LN involvement was based on various criteria such as cystic changes, 
hyperechogenicity, loss of hilar echogenicity (fat center), internal microcalcifications, poorly 
defined irregular borders, shape/dimension ratio, compressibility, vascularity, size >5 mm in its 
shortest diameter  and round shape (Figure 1, page 58) [85, 104, 107, 121, 122]. In our study, a 
node was considered suspicious if at least one of these criteria was met. As for loss of hilar 
echogenicity on nodes smaller than 5 mm, an additional criterion was needed to reach the level 
of suspicious LN. The surgical exploration was guided by U/S mapping. Suspicious LNs were 
removed based on the compartment-oriented approach without further dissection. On 
histopathology, LNs with a diameter less than 5 mm were examined by one-slice specimen. 
Two-slice specimen examination was used for the LNs having a diameter greater than 5 mm.  
Statistical analyses were performed using SPSS software, version 20. Continuous variables were 
analyzed with the mean ± standard deviation, and X2 was used for categorical data.   
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Results 
 
Among 263 patients who underwent thyroid surgery, 261 had undergone U/S mapping. 
Suspicious LNs had been found in 154 cases. Despite positive U/S mapping, 18 cases were 
excluded from the study due to the absence of LNs in the surgical specimen in 3 patients, the 
absence of pathological results in 1 patient, the absence of neck compartment dissection in 11 
patients, and a change in surgical planning in favor of palliative tracheotomy in 1 patient and 
hemithyroidectomy in 2 patients. Therefore, results were obtained after analyzing 136 cases of 
positive U/S mapping in 120 patients (Table II, page 55). 
The patients’ mean age was 49.9 (16-90, SD 16.2). Among those patients, 89 were female 
(74.1%) and 31 male (25.9%). Nine patients had been operated twice, two patients three times, 
and one patient four times. Out of 120 patients, histopathological analysis indicated 110 PTCs, 
8 medullary cancers, 1 follicular cancer and 1 Hurthle cell tumor. In 87 cases, compartment-
oriented surgical excision of suspected LNs along with thyroidectomy had been performed 
(primary surgeries) and 49 procedures had been carried out for recurrent disease (secondary 
surgeries). During the data collection period (02/2014-09/2014), radiological findings of 
locoregional recurrent disease were noted in 26 patients (21.6%). On U/S mapping, there were 
40 cases in group A (29.4 %) and 96 cases in group B (70.6%). On histopathology, there were 
22 cases in group 1 (16.2%), 41 cases in group 2 (31.1%) and 73 cases in group 3 (53.7%) (Table 
III, page 56). Among these groups, the chi-square test resulted in X2 = 10.33 (p = 0.006).  
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The PPVs of ultrasound mapping were calculated for LC alone, CC alone and both LC/CC. For 
LC, 76 cases out of 89 were confirmed positive on pathological examination, resulting in LC-
PPV=85.39% (95% CI 0.76-0.91). For CC, there were 66 positive cases out of 82, resulting in 
CC-PPV=80.48% (95% CI 0.7-0.87). Finally, for both LC/CC, 114 out of 136 cases were 
confirmed positive, with a LC/CC-PPV=83.82 (95% CI 0.76-0.89). Positive results on 
histopathology were derived following the examination of 1766 and 659 LNs removed from the 
LC and CC (Table IV, page 57).  
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Discussion 
 
This study examined the qualitative and quantitative reliability of U/S mapping of thyroid cancer 
in a single institution. Our results confirmed that U/S mapping is a reliable tool for detecting 
affected LNs. With an LC/CC-PPV value of 83.82% together with advantages such as 
simplicity, ease in terms of performance, wide availability, comparatively low price, non-
invasiveness and lack of radiation [113], U/S mapping is an excellent tool for surgery guidance. 
The relatively low rate of detection of metastatic LNs in the CC might be explained by 
anatomical limitations in that area of the neck, such as the clavicle, sternum and tracheal air 
shadow [106, 118] 
Micrometastases (<2 mm) in patients undergoing prophylactic LN dissection were found in up 
to 80% of individuals [113, 123]. Nevertheless, such micrometastases are not clincially relevant, 
as most patients with PTC do not develop palpable lymphadenopathies. On the contrary, patients 
presenting with macrometastases (> 2 mm) have 5% to 40% persistent/recurrent (P/R) disease 
after surgery [124, 125]. P/R disease may be detected by TSH-stimulated serum thyroglobulin 
levels followed by confirmatory U/S guided FNA cytology [124, 126]. P/R disease has a 
tremendous impact on quality of life and despite the additional therapeutic interventions, 10% 
of patients die from it [113]. Reoperation of P/R disease involves many difficulties because the 
extensive scarring from previous surgery can obscure normal anatomy, which in turn contributes 
to longer operative times and increased morbidity [127]. U/S mapping guides the surgeon for 
precise neck dissection, resulting in decreased locoregional tumor recurrence and lower risk of 
postsurgical complications due to reoperation. To analyze this test more thoroughly, we decided 
to go one step further in our study by evaluating not only PPV but also the quantitative reliability 
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of the test, which, to our knowledge, had not been done before. Such an approach seemed highly 
valuable since patients with multiple positive LNs have been shown to be at greater risk of 
recurrence [128]. Based on the quantitative results of U/S mapping, patients can be stratified 
according to the level of risk of recurrent disease, which in turn will help in better selecting 
surgical candidates. The use of U/S mapping to plan compartment-oriented LN dissection could 
therefore benefit patients undergoing thyroid cancer surgery, as recognized by the American 
Thyroid Association [128]. In this study, results showed a statistically significant association 
between U/S mapping analysis and LN pathological examination, indicating that U/S mapping 
is an effective tool in the armamentarium of quantitative prediction for lymphatic spread in 
thyroid cancer. Another notable observation was derived by analyzing the false positive cases 
on U/S mapping. In 10 out of 22 cases (45.4%), patients were suffering from Hashimoto's 
thyroiditis which was mimicking affected LNs in thyroid cancer. The retrosternal localization 
and small size (<5 mm) of the affected LNs made it extremely difficult to distinguish them from 
metastatic LNs. Consequently, we believe that Hashimoto's thyroiditis might be considered a 
limiting factor for U/S mapping in patients with suspicion of thyroid cancer. Another major 
subject of discussion is the test’s specificity and sensitivity. In fact, it is impossible to calculate 
either sensitivity or specificity since negative findings on U/S cannot be considered true 
negatives because of the lack of supporting “gold standard” results. In the literature, these two 
values have a very wide range (from 29% to 100%) depending on the study design and chosen 
“gold standard” methods, as shown by Wu et al. in their meta-analysis [129]. We therefore 
believe that the best way to solve this contradiction is to conduct a prospective study with long-
term followup of negative cases on U/S mapping. 
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Conclusion: U/S mapping is a reliable tool for guiding surgical dissection of the neck, both for 
a primary tumor and for P/R disease. It has a sufficiently high PPV and strong quantitative 
association with histopathological analysis which makes it possible to focus on patients with 
higher risk of recurrent disease. Meanwhile, there might be some limitations to the test in cases 
such as thyroiditis, and further research needs to be done to obtain more reliable values for both 
sensitivity and specificity. 
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Table I: AJCC 7th Edition/TNM Classification System for Differentiated Thyroid Carcinoma 
 
T0     No evidence of primary tumor 
T1a   Tumor ≤1 cm, without extrathyroidal extension 
T1b   Tumor >1 cm but ≤2 cm in greatest dimension, without extrathyroidal extension 
T2     Tumor >2 cm but ≤4 cm in greatest dimension, without extrathyroidal extension 
T3     Tumor >4 cm in greatest dimension limited to the thyroid or  
       Any size tumor with minimal extrathyroidal extension (e.g., extension into sternothyroid 
muscle or perithyroidal soft tissues) 
T4a   Tumor of any size extending beyond the thyroid capsule to invade subcutaneous soft tissues, 
larynx, trachea, esophagus, or recurrent laryngeal nerve       
T4b   Tumor of any size invading prevertebral fascia or encasing carotid artery or mediastinal vessels 
 
 
N0     No metastatic nodes 
N1a   Metastases to level VI (pretracheal, paratracheal, and prelaryngeal/Delphian lymph nodes) 
N1b   Metastases to unilateral, bilateral, or contralateral cervical (levels I, II III, IV, or V) or    
retropharyngeal or superior mediastinal lymph nodes (level VII) 
 
 
M0    No distant metastases 
M1    Distant metastases 
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Table II: Surgical and histopathological characteristics of patients who underwent ultrasound mapping followed by 
neck dissection 
 
 
 
 
 
 
  
No. of patients/cases 120/136 
Gender (F/M) 89(74.1%)/31(25.9%) 
Mean age ± SD/Min-Max 49.9±16.2/16-90 
No. of primary/secondary surgeries 87/49 
No. of postsurgical complications  3 
Locoregional recurrence on U/S followup  26 (21.6%) 
 
Histopathology (patients/result) 
110/papillary 
8/medullary 
1/follicular 
1/Hurthle cell 
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Table III: Cross-tabulation of the results among the groups of U/S mapping and histopathology 
Mapping Histopathology 
 1 (0 PLN) 
 
2 (1 or 2 PLN) 3 (3< PLN) Total 
A (1 or 2 SLN) 10 17 13 40 
B (3≥ SLN) 12 24 60 96 
Total 22 41 73  
 
                  SLN: suspicious lymph nodes. PLN: positive lymph nodes 
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Table IV: Descriptive statistics of the removed LNs according to compartments 
 
 
 
 
 
 
 
 
 
 
 Lateral compartment Central compartment 
No. of dissected 
compartments 
91 93 
 Positive LN Total LN Positive LN Total LN 
Mean No. of LN ± SD 4.21 ± 0.66 19.41± 1.6 3.24± 0.42 7.09 ±0.61 
Median No. of LN 
(Min/Max) 
2(0/49) 17(1/72) 2(0/24) 5(1/34) 
Sum of LN 383 1766 301 659 
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Figure 1: (A) Ultrasonography of the neck. (B) Cancerous nodule detected on ultrasound (arrow). (C) 
Microcalcifications in the cancerous nodule 
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Discussion 
 
The main goal of this study was to evaluate the diagnostic reliability of preoperative ultrasound 
(U/S) cervical mapping and highlight the relevance of this tool as a primary imaging modality 
for detecting and localizing metastatic nodal propagation in patients with thyroid cancer. 
Considering the results we obtained, it is fair to assert that U/S mapping is a powerful weapon 
in experienced hands because it can alter surgical planning and ameliorate overall patient 
outcomes by helping to minimize the risk of P/R disease.  
Although many studies have tried to describe comprehensive qualitative evaluation by 
calculating not only the PPV of U/S cervical mapping but also its specificity and sensitivity, we 
appear to be the first group to adopt the quantitative evaluation method for this test by estimating 
the correlation between imaging results and histopathology. The idea behind this approach is 
strongly associated with prognostic factors for P/R PTC. According to some authors, several 
characteristic features of nodal metastases such as the number of metastatic lymph nodes (LNs), 
their size, and the presence of extranodal extension are the principal factors impacting the 
incidence of P/R disease [130, 131]. In particular, Ito et al. showed that patients with 5 or more 
clinically apparent metastases have a higher risk of locoregional recurrence [131]. Furthermore, 
the histopathology results of the neck dissection specimens confirmed this hypothesis as the 
patients with multiple positive nodes proved to be at greater risk of P/R disease [128]. This 
observation allows us to use the number of suspicious LNs on U/S mapping as useful criteria 
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for targeting the patient group with higher risk of P/R disease, which in turn may alter the 
treatment plan according to the risk group.  
Our study showed that U/S mapping is an excellent tool for predicting the number of possibly 
affected LNs, which helps us stratify patients according to their risk of P/R disease and then 
adjust the extent of surgery based on that risk level. 
Regarding the qualitative analysis, our results corroborate previously published outcomes. U/S 
mapping was shown to be a very reliable test with a PPV of over 80% and 85% in the central 
and lateral compartments respectively. The difference in the detection rate between the two 
compartments is due to anatomical limitations in the central compartment.  
Although we obtained good results in terms of the ability of U/S mapping to detect suspicious 
LNs, the current study’s design did not allow us to calculate either test sensitivity or specificity, 
which is one of the major limitations of our study. In the literature, these two features of the test 
have a very wide range [129] as there is no universal agreement on what should be considered 
the “gold standard”  which could confirm or refute the negative results of preoperative lymph 
node staging by U/S mapping. Another weakness of our study is its limited generalizability, 
which is otherwise known as external validity. Our data originated from a single institution, 
which raises some questions about the extent to which the results can be applied in other clinical 
environments. This concern is supported by the fact that U/S mapping is a very operator 
dependent procedure, and this can impact the test’s predictive reliability depending on the 
operator’s experience, which can vary at different hospitals.  
During the data analysis we also had some unexpected findings. In almost half of the false 
positive U/S mapping cases, the patients were suffering from Hashimoto's thyroiditis. After 
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investigating possible explanations, we concluded that the small size (<5 mm) and localization 
of the affected LNs did not allow for adequate visualization by U/S, in which case the inflamed 
LN could mimic a cancerous one. 
Conclusion 
 
In patients with thyroid cancer, preoperative LN staging has enormous relevance as it impacts 
surgical planning and overall outcomes. Preoperative U/S cervical mapping helps in risk 
stratification for P/R disease. It is useful in identifying the patients who would benefit most from 
subsequent compartment-oriented neck dissection. Nevertheless, further study may be 
warranted to calculate both the specificity and sensitivity of the test. 
We recommend that U/S mapping be used as a routine imaging modality in order to prevent P/R 
disease and reduce morbidity caused by repeated surgeries. 
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